Synmosa Biopharma Cash Flow Reinvestment Rate
Synmosa Biopharma cash flow reinvestment rate. Synmosa Biopharma (4114) has a Cash Flow Reinvestment Rate of 5.31x as of December 2025, reinvesting NT$986.18 Million (capex NT$59.46 Million plus investments NT$926.72 Million) from operating cash flow of NT$185.72 Million. Explore 4114 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Synmosa Biopharma (2015–2025)
Cash flow reinvestment rate of Synmosa Biopharma from 2015 to 2025. Historical reinvestment intensity for Synmosa Biopharma across 9 annual periods. Explore 4114 capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Synmosa Biopharma Cash Flow Reinvestment Rate by Year (2015–2025)
Synmosa Biopharma cash flow reinvestment rate by year from 2015 to 2025. Year-by-year capital reinvestment analysis for Synmosa Biopharma. For the full cash flow conversion analysis, see cash efficiency ratio of Synmosa Biopharma.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.64x | NT$676.44 Million | NT$411.57 Million | NT$281.13 Million | ▲ +294.7% |
| 2024 | 0.42x | NT$325.05 Million | NT$780.62 Million | NT$269.65 Million | ▼ -78.4% |
| 2023 | 1.93x | NT$987.64 Million | NT$511.93 Million | NT$269.77 Million | ▲ +437.5% |
| 2022 | 0.36x | NT$226.22 Million | NT$630.25 Million | NT$129.29 Million | ▲ +63.6% |
| 2021 | 0.22x | NT$97.47 Million | NT$444.29 Million | NT$93.06 Million | ▼ -77.2% |
| 2020 | 0.96x | NT$244.96 Million | NT$254.40 Million | NT$154.41 Million | ▼ -97.3% |
| 2018 | 35.49x | NT$567.76 Million | NT$16.00 Million | NT$314.43 Million | ▲ +473.8% |
| 2016 | 6.19x | NT$1.46 Billion | NT$236.48 Million | NT$423.92 Million | ▼ -66.2% |
| 2015 | 18.30x | NT$431.85 Million | NT$23.60 Million | NT$369.26 Million | — |